Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

@article{GmezBenito2007MembraneEO,
  title={Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.},
  author={Mar{\'i}a G{\'o}mez-Benito and Mar{\'i}a Jos{\'e} Mart{\'i}nez-Lorenzo and Alberto Anel and Isabel Marzo and J. M. Goldspiel U. S. Naval},
  journal={Experimental cell research},
  year={2007},
  volume={313 11},
  pages={2378-88}
}
The improved recombinant form of the death ligand Apo2L/TRAIL (Apo2L/TRAIL.0) is not cytotoxic for normal human cells and is a good candidate for the therapy of multiple myeloma (MM), a B-cell neoplasia that remains incurable. We have analyzed the molecular determinants of myeloma sensitivity to Apo2L/TRAIL.0 in a number of MM cell lines, the mechanisms of resistance and a possible way of overcoming it. Expression of one death receptor for Apo2L/TRAIL (DR4 or DR5) is sufficient to transduce… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…